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ABSTRACT 
Corticosteroids are widely used for its anti-inflammatory and immunosuppressant properties. It can be given by systemic, 
oral or inhalation. Corticosteroids are associated with a wide range of adverse events which include diabetes, osteoporosis, glaucoma 
and psychiatric mood swings. Mood swings can be observed within first two weeks, but discontinuation of drug can reverse this. 
Psychiatric disorders with prescription corticosteroids are classified as substance-induced mood disorders according to DSM-IV 
criteria. Mania is more commonly found than depression, but depression is triggered by steroid withdrawal. All these psychiatric 
symptoms are reversible and disappear with the discontinuation of drug. 
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INTRODUCTION 
Corticosteroids are a collection of steroid hormones 
produced within the adrenal cortex or made synthetically. They 
are of two categories: glucocorticoids which suppress 
inflammation and immunity and assist in the breakdown of fat, 
carbohydrates, and proteins, or as mineralocorticoids (salt-
retaining) that regulate the salt and water stability within the 
body. 
"Anabolic" refers to muscle building, and "androgenic" 
refers to elevated male sex traits. They are variations of 
testosterone. Anabolic steroid abuse can also cause mental 
problems like paranoid jealousy, severe irritability, delusions, 
and impaired judgment [1]. 
The outer portion of adrenal gland referred to as 
cortex produces naturally occurring corticosteroids, 
hydrocortisone (Cortef) and cortisone. Synthetic corticosteroids 
mimic the actions of naturally occurring corticosteroids and can 
be used to update corticosteroids in people with adrenal glands 
that are unable to provide adequate amounts of corticosteroids, 
they include betamethasone (Celestone), prednisone 
(Prednisone Intensol), prednisolone (Orapred, Prelone), 
triamcinolone (Aristospan Intra-Articular, Aristospan  
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Intralesional, Kenalog), methylprednisolone (Medrol, Depo-
Medrol, Solu-Medrol) and dexamethasone [2]. 
Glucocorticoids are capable to suppress inflammation 
and acts in different varieties of anti-inflammatory and 
autoimmune diseases makes them among the most often 
prescribed classes of medicine [3]. 
Glucocorticoids have turn out to be essential in almost 
every subspecialty of medicine. Symptoms for short-term acute 
steroid therapy can be seen in exacerbation of the chronic 
obstructive pulmonary disease, acute gout, chemotherapy 
protocols, bacterial meningitis and in pregnant women for fetal 
lung maturation, to name some. Disease processes benefiting 
from persistent glucocorticoid use consist of the following: 
pulmonary diseases such as idiopathic interstitial pneumonia, 
hypersensitivity pneumonitis and sarcoidosis; autoimmune 
conditions; neurologic diseases such as myasthenia gravis and 
multiple sclerosis; and inflammatory bowel diseases (IBS) [4]. 
Short-term corticosteroid use is associated with 
generally mild side effects, consisting of cutaneous effects, 
electrolyte abnormalities, hypertension, hyperglycemia, 
pancreatitis, hematologic, immunologic, and neuropsychological 
effects, although occasionally, clinically significant side effects 
may occur. Long-term corticosteroid use can be associated with 
the more serious sequel, which includes osteoporosis, aseptic 
joint necrosis, adrenal insufficiency, gastrointestinal, hepatic, 
and ophthalmologic effects, hyperlipidemia, growth 
suppression, and possibly congenital malformations [4]. 
Common corticosteroids induced psychiatric disorders 
(CIPD) include mania, depression, psychosis, and delirium. The 
females and people with prior CIPD are at elevated risk. 
Depression and mania are the most frequent behavioral side 
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effects, accompanied by psychosis and delirium. There may be 
different etiologies for these psychiatric disorders; they need to 
be nicely distinguished from corticosteroid facet results [5]. 
Case reports of psychiatric side effects which include 
mania, depression, mood liability, or even psychosis during 
corticosteroid therapy are numerous (table 1). They may be 
prescribed at physiological doses for replacement therapy when 
endogenous production is impaired. 
 
Table No. 1: Studies on CIPD. 
Study Indication Symptom Drug 
Laurence Fardet Miscellaneous suicide or suicide attempt,severe 
neuropsychiatric disorders 
oral glucocorticoids 
Tutkunkardas and 
Mukaddes (2010) 
T-ALL Mood lability, irritability, anger outburst, suicidal 
ideation 
Dexamethasone 
Ularntinon et al. (2010) T-cell ALL/Pre-B-
cell ALL 
Elation, grandiose ideation, prophetic delusion, 
insomnia,Agitation, irritability,pressured 
Prednisone/ 
Dexamethasone 
Airagnes et al. (2011) CLL Insomnia, elation, paranoid psychosis, homicide Methylprednisolone 
Cassidy et al. (2012) ALL Insomnia, elation, grandiose delusion Dexamethasone 
Kimmel and Combs (2012) Metastatic breast 
cancer D 
Agitation, insomnia, irritability, thought disorder Dexamethasone 
Hechtman et al. (2013) ALL Agitation, auditory and visual hallucination, 
pressured speech 
Prednisone 
Zincir et al. (2014) ALL Depressive symptoms, lost appetite, passive death 
wish and suicide attempt 
Dexamethasone 
 
Corticosteroid and Psychiatric Disorders: 
Corticosteroid has been related to a wide range of 
psychiatric symptoms since their introduction in 1950's4. These 
are all reported to be reversible. Those include mood disorders 
(hypomania, mania, mixed states, depression), anxiety and panic 
disorder [6-7], delirium, suicidal thinking and behavior in the 
context of affective syndromes or delirium, aggressive behavior, 
insomnia, dementia and agitation with clear consciousness, 
depersonalization; and, isolated cognitive impairments [8-9]. 
Glucocorticoids are extensively prescribed for a 
variety of skin diseases and are known to cause a variety of 
neuropsychiatric as well as somatic side effects. The incidence 
of neuropsychiatric results of steroids vary from 2% to 60% [10]. 
Corticosteroids are widely used in asthma, COPD and 
respiratory illness. Gift et al has suggested an elevated degree of 
depression in a collection of COPD patients on corticosteroids 
[11]. 
According with a case-control study conducted in 
Texas, patients receiving chronic corticosteroid therapy have 
smaller hippocampal volumes, lower N-acetyl aspartate ratios, 
and declarative memory deficits as compared with controls. 
Hippocampal volume reduction, declarative memory deficits, 
and cortisol elevations are reported in people with major 
depressive disorder [12]. 
Higher the corticosteroid dose, higher the risk of 
psychiatric symptoms. In patients taking prednisone, the Boston 
Collaborative Drug Surveillance Project determined the 
incidence of psychiatric side effects to be: 1.3% in patients 
taking <40 mg,4.6% in those taking 41 to 80 mg and 18.4% in 
those taking >80 mg [13]. 
Olsen et al. found a significant correlation between 
mood lability and prednisolone dose, in 25% of patients during 
a 6-week taper from 40 mg/day to zero in 32 patients with 
alopecia areata14. Studies conclude that out of 16 patients with 
first-onset mood symptoms after corticosteroid use, a 
retrospective chart review determined 7 had recurrent manic 
and depressive symptoms unrelated to additional corticosteroid 
use15. These suggest that corticosteroid use may contribute to 
the onset of bipolar I illness [14-18]. 
Hall et al. reported that 86% of patients with 
psychiatric side-effects developed within 1 week of starting 
treatment [19]. While Ling et al. suggested that the psychiatric 
sequelae of corticosteroid treatment generally occurred within 
2 weeks [17]. 
Cognitive impairment has been reported in systemic 
corticosteroid use. Varney et al have reported in a case series of 
6 patients taking prednisolone 20 to 100 mg daily, that they 
developed cognitive problems. These included functional 
deficits, attention issues, concentration, and verbal memory.[20] 
All these were reversible. There have also been reports 
suggesting that dexamethasone can cause deficits in declarative 
memory. Same were reported on the high dose of 
hydrocortisone use however those are reversible and can be 
fixed by the discontinuation of drug [21-23]. 
According to a cross-sectional observational study 
conducted in eastern India, on patients attending dermatology 
department, receiving corticosteroids in any total topical 
corticosteroids prescribed, the trend revealed that high potency 
corticosteroids were majorly prescribed (38%), accompanied 
by those of ultra-high potency (35%) and medium potency 
(19%). The study concluded that misuse of topical 
corticosteroids has a huge impact on dermatological practices 
which needs multi-dimensional interventions, regarding 
educational, lawful and managerial approaches to overcome it 
[24]. 
The studies have counseled that mania is more 
common than depression. As reported by Wada et al, 85% of 
steroid-induced mood changes were primarily manic in nature 
[15]. This report is complementary to Naber et al., where 26% of 
people developed mania in comparison to 10% depression, 
during corticosteroid therapy [16]. Also, based on an American 
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study mood changes were observed even during brief courses of 
corticosteroids at modest dosages and these symptoms were 
primarily manic, not depressive. In fact, people with depression 
have displayed  improvement [25]. However a study by Bolanos 
et al, unlike short-term prednisone therapy, long-term therapy 
can be more associated with depressive than manic symptoms 
[26]. 
Patients who did not experience psychiatric side 
effects with corticosteroids in the past don’t mean it won’t 
develop later. One report examined 17cases of steroid-induced 
psychiatric illness in patients with previous exposure to 
corticosteroid therapy. Six patients had previous psychiatric 
side effects while taking corticosteroids and 11 did not [27]. 
Management of CIPD: 
Antidepressants and mood stabilizers are prescribed 
for CIPD [27]. Patients in most cases self‐manage destructive 
consequences experienced and will have only limited 
information about CIPD. Education, support, and ongoing care 
for patients experiencing CIPD are insufficient. Health 
professionals need to broaden patient‐ and family‐targeted 
educational sources for potential, unpredictable, and adverse 
steroid side‐effects [28]. 
Lithium and phenytoin can prevent mood symptoms 
associated with corticosteroids based on some controlled trials 
whilst some uncontrolled trials recommend that antipsychotics, 
anti-seizure medications and perhaps some antidepressants can 
be beneficial in normalizing corticosteroid-related mood 
changes. Additionally, lamotrigine and memantine were proven 
to reverse, at least partially, the declarative memory effects of 
corticosteroids [29]. 
In a study carried out in cancer patients, self-
management of signs blanketed, particular strategies to cope 
with: (i) sleeplessness, included "now not fighting it " and 
accepting sleep medication,(ii) heightened strength, mandatory 
self-rest, making "to do "lists, and spreading chores over three 
days in preference to two, (iii) terrible awareness, blanketed 
writing matters down, (iv) misery over weight gain. through 
controlling urge for food, (v) alcohol consumption, such as 
counseling,(vi) heightened aggression, by means of explaining 
steroid results to family and seeing a counselor, and (vii) feeling 
sorry for oneself by in search of assist from a psychiatry 
registrar. Some have been provided medicinal drugs to 
ameliorate steroid facet-consequences. While occasional 
individuals located medicinal drugs beneficial for reducing 
“rushing”, head “humming”, and sleep disturbance, others did 
not take them, likely due to worries about toxicity and 
dependency [28]. 
Side effects of corticosteroids in hematologic sufferers 
range from negligible to intense, which include paranoia, 
aggressiveness, marked sleep disturbance, and mental 
disturbance related to intense weight gain and changes in body 
image [28]. 
In a study carried out in 12 outpatients with 
corticosteroid-induced mood disorders the records advised that 
olanzapine is nicely tolerated and appears to be beneficial for 
mood disturbances associated with corticosteroid remedy [30]. 
Falk et al. pronounced that lithium pretreatment would possibly 
prevent corticosteroid-caused mood symptoms. While as 14% 
of patients receiving corticotropin therapy suffered from mood 
signs and symptoms, none of the patients receiving 
corticotrophin following lithium pretreatment had a mood 
disturbance [31]. 
Role of Clinical Pharmacist in CIPD: 
Clinical pharmacist play a major role in identifying 
CIPD.Proper patient history interview and therapeutic 
monitoring can aid this. It is also the duty of clinical pharmacist 
to provide proper counseling to the patient as well as 
intervention once CIPD is identified. Prescription auditing and 
maintaining a daily progression chart for the patient will help in 
making early interventions. 
REFERENCES: 
1. Anabolic Steroids.National Institute on Drug Abuse; 
National Institutes of Health; U.S. Department of Health 
and Human Services.Updated March 2016. 
2. https://www.medicinenet.com/corticosteroids-
oral/article.html 
3. Kendall EC. Nobel lecture: The development of cortisone 
as a therapeutic agent. Nobelprize.org. December 11 
1950. 
4. Buchman AL. Side effects of corticosteroid therapy. J Clin 
Gastroenterol 2001;33(4):289-294. 
5. Cerullo MA. Expect psychiatric side effects from 
corticosteroid use in the elderly. Geriatrics 2008;63(1): 
15-18. 
6. Raskin DE. Steroid-induced panic disorder. Am J Psych 
1984;1641:1647. 
7. Charbonneau Y, Ravindran AV. Successful treatment of 
steroid-induced panic disorder with fluvoxamine. J Psych 
Neurosci 1997;22:346–347. 
8. Braunig P, Bleistein J, Rao ML. Suicidality and 
corticosteroid-induced psychosis. Biol Psych 1989;26: 
209–210. 
9. Finkenbine RD, Frye MD. Case of psychosis due to 
prednisone-clarithromycin interaction. Gen Hosp Psych 
1998;20:325–326. 
10. Ularntinon S, Tzuang D, Dahl G, Shaw RJ. Concurrent 
Treatment of Steroid-Related Mood and Psychotic 
Symptoms with Risperidone. Pediatrics 2010;125(5): 
e1241-1245. 
11. Gift AG, Wood RM, Cahill CA. Depression, somatization 
and steroid use in chronic obstructive pulmonary 
disease. Int J Nurs Stud 1989;26:281–286. 
12. Brown ES, Woolston J, Frol A, Bobadilla L, Khan DA, 
Hanczyc M,et al. Hippocampal volume, spectroscopy, 
cognition, and mood in patients receiving corticosteroid 
therapy. Biol Psych 2004;55(5):538–545. 
13. The Boston Collaborative Drug Surveillance Program. 
Acute adverse reactions to prednisone in relation to 
dosage. Clin Pharmacol Ther 1972;13:694-698. 
14. Olsen EA, Carson SC, Turney EA. Systemic steroids with 
or without 2% topical minoxidil in the treatment of 
alopecia areata. Arch Dermatol 1992;128(11):1467-
1473. 
15. Wada K, Yamada N, Sato T et al. Corticosteroid-induced 
psychotic and mood disorders: diagnosis defined by 
DSM-IV and clinical pictures. Psychosom 2001;42(6): 
461–466. 
16.  Naber D, Sand P, Heigl B. Psychopathological and 
neuropsychological effects of 8-days’ corticosteroid 
treatment. A prospective study. Psychoneuroendocrinol 
1996;21(1):25–31. 
Vijayalakshmi R, et al.                                                                                                                         J Sci Res Pharm, 2019;8(2):8-11 
© 2012, JSRP. All Rights Reserved 
http://www.worldinventiapublishers.com/ 
17. Ling MH, Perry PJ, Tsuang MT. Side effects of 
corticosteroid therapy. Psychiatric aspects. Arch Gen 
Psych 1981;38(4):471–477. 
18.  Narrow WE, Rae DS, Robins LN, Regier DA. Revised 
prevalence estimates of mental disorders in the United 
States: using a clinical significance criterion to reconcile 
2 surveys’ estimates. Arch Gen Psych 2002;59(2):115-
123. 
19. Hall RC, Popkin MK, Stickney SK, Gardner ER. 
Presentation of the steroid psychoses. J Nerv Ment Dis 
1979;167(4):229–236. 
20.  Varney NR, Alexander B, MacIndoe JH. Reversible steroid 
dementia in patients without steroid psychosis. Am J 
Psych 1984;141(3):369–372. 
21. Wolkowitz OM, Rubinow D, Doran AR et al. Prednisone 
effects on neurochemistry and behavior. Preliminary 
findings. Arch Gen Psych 1990;47(10):963–968. 
22. Newcomer JW, Craft S, Hershey T, Askins K, Bardgett ME. 
Glucocorticoid-induced impairment in declarative 
memory performance in adult humans. J Neurosci 
1994;14(4):2047–2053. 
23. Newcomer JW, Selke G, Melson AK, Hershey T, Craft 
S,Richards K, Alderson AL. Decreased memory 
performance in healthy humans induced by stress-level 
cortisol treatment. Arch Gen Psych 1999;56(6):527–533. 
24. Mukherjee, et al. Assessment of corticosteroid utilization 
pattern among dermatology outpatients in a tertiary care 
teaching hospital in Eastern India. Int J Green Pharm 
2016;10(4):S178-182. 
25. Brown ES, Suppes T, Khan DA, Carmody TJ 3rd. Mood 
changes during prednisone bursts in outpatients with 
asthma. J Clin Psychopharmacol 2002;22(1):55-61. 
26. Bolanos SH, Khan DA, Hanczyc M, Bauer MS, Dhanani N, 
Brown ES. Assessment of mood states in patients 
receiving long-term corticosteroid therapy and in 
controls with patient-rated and clinician-rated scales. 
Ann Allergy Asthma Immunol 2004;92(5):500-5. 
27. Wada K, Yamada N, Suzuki K, et al. Recurrent Cases of 
Corticosteroid-Induced Mood Disorder: Clinical 
Characteristics and Treatment. J Clin Psych 
2000;61(4):261-267. 
28. Clifton D, Ross M, O'Callaghan C.Psychiatric sequelae of 
corticosteroid use in hematology in Australia: A 
qualitative study. Nurs Health Sci 2018;20(1):125–131. 
29. Brown ES. Management of psychiatric side effects 
associated with corticosteroids. Expert Rev Neurother 
2003;3(1):69-75. 
30. Brown ES, Chamberlaina W, Dhanania N, Paranjpea P, 
Carmodya TJ, Sargeanta M. An open-label trial of 
olanzapine for corticosteroid-induced mood symptoms. J 
Affect Disorders 2004;83(2-3):277-281. 
31. Falk WE, Mahnke MW, Poskanzer DC. Lithium 
prophylaxis of corticotropin-induced psychosis. JAMA 
1979;241(10):1011– 1012. 
 
 
 
 
 
 
How to cite this article: 
Vijayalakshmi R, Sujitha P.J. CORTICOSTEROID INDUCED PSYCHIATRIC DISORDERS. J Sci Res Pharm 2019;8(2):8-11. 
 
 
 
 
Conflict of interest: The authors have declared that no conflict of interest exists. 
Source of support: Nil 
